What is Aobiome?
Aobiome is a pioneering clinical-stage biotechnology firm focused on the therapeutic potential of the human microbiome. The company specializes in the development of Ammonia Oxidizing Bacteria (AOB) to restore biological homeostasis, targeting a diverse range of conditions including acne, eczema, rosacea, and hypertension. By repopulating beneficial bacteria on the skin, Aobiome aims to modulate the immune system and treat complex inflammatory and systemic diseases. Their platform represents a novel paradigm in medicine, moving beyond traditional small-molecule drugs to harness the power of living bacteria for long-term health optimization.
How much funding has Aobiome raised?
Aobiome has raised a total of $33.7M across 4 funding rounds:
Private Equity
$630K
Private Equity
$576K
Private Equity
$2.5M
Private Equity
$30M
Private Equity (2013): $630K, investors not publicly disclosed
Private Equity (2014): $576K, investors not publicly disclosed
Private Equity (2015): $2.5M, investors not publicly disclosed
Private Equity (2017): $30M featuring iCarbonX
Key Investors in Aobiome
iCarbonX
A digital health pioneer focused on building a global platform for digitizing and analyzing life through multi-omics, artificial intelligence, and experiential data.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Aobiome?
With the recent capital infusion, Aobiome is well-positioned to scale its clinical programs and expand its preclinical research into pulmonary and gastrointestinal disorders. The strategic focus will likely center on navigating late-stage clinical trials and refining the delivery mechanisms for its AOB-based product candidates. As the company matures, it will likely seek to solidify its intellectual property portfolio and explore commercialization pathways that integrate its microbiome technology into standard dermatological and systemic care protocols. The firm remains a critical player in the biotech landscape, with the potential to redefine treatment standards for chronic inflammatory conditions.
See full Aobiome company page
